A Phase 2/3 interventional study of CTO0303-A and CTO0303-B in Pupillary Dilation Effect During Cycloplegic Refraction, sponsored by Taejoon Pharmaceutical Co., Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 4 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.
Sponsored by Taejoon Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Diagnostic
This is a prospective randomized study compared with active control arm.
This is a prospective randomized study compared with active control arm. The investigators compare the pupil size in subject when 30 minutes after administering IP (CTO0303 or active control).
37 studies on the registry are indexed under Mydriasis; 4 are open to participants now.
This study's planned enrollment of 156 is above the median of 61 across 35 interventional studies indexed under Mydriasis.
Browse Mydriasis studies →Taejoon Pharmaceutical Co., Ltd. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CTO0303-A
Drug: CTO0303-B
Drug: CTO0303-C
eye drop, 1 drop 3 times (every 5 minutes) a day
eye drop, 1 drop 3 times (every 5 minutes) a day
eye drop, 1 drop 3 times (every 5 minutes) a day
pupillary dilation effect at 30 minutes after administration
The pupil size is measured using a pupillometer 30 minutes after IP administration
Time frame: From enrollment to the end of treatment at 1 day.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taejoon Pharmaceutical Co., Ltd. →